0.00Open0.20Pre Close0 Volume5 Open Interest24.50Strike Price0.00Turnover0.00%IV23.75%PremiumNov 1, 2024Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma99.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Stock Discussion
$Nxu Inc (NXU.US)$ grab some on your way out.
After the dual-antibody drug data from Summit Therapeutics (SMMT.US) defeated the "drug king", it was listed as Citigroup's preferred stock and the target price was raised.
No comment yet